Anti-diabetic treatment regulates pro-fibrotic TGF-β serum levels in type 2 diabetics

Diabetology & Metabolic Syndrome

Sabrina Ehnert¹  Karl F Braun⁴  Andreas K Nussler¹  Thomas Forst³  Thomas Freude¹  Stefan Pscherer² 

[1] BG Trauma Center Tübingen, Schnarrenbergstraße 95, Tübingen 72076, Germany;Klinikum Traunstein, Diabetes Department, Cuno-Niggl-Straße 3, Traunstein 83278, Germany;Department of Endocrinology, ikfe Mainz/University Mainz, Parcusstraße 8, Mainz 55116, Germany;Department of Trauma Surgery, Klinikum rechts der Isar, Technische Universität München, Ismaningerstraße 22, Munich 81675, Germany

关键词: Glucose;    Proinsulin;    Insulin;    TGF-β;    Diabetes mellitus type 2;   

Others  :  821584
DOI  :  10.1186/1758-5996-5-48

 received in 2013-03-12, accepted in 2013-08-28,  发布年份 2013

【 摘 要 】

Background

The single-center, open-label, four-arm, exploratory study investigates the relation of different anti-diabetics to serum levels of active TGF-β, a known pro-fibrotic stimulus, before and after a defined test meal.

Findings

We investigated sera of patients with type 2 diabetes mellitus (T2DM) treated with metformin and sulfonylurea, insulin glargine or a DPP-4 inhibitor (DPP4i). Patients’ sera were analyzed before and 5 h after a defined test meal at intervals of 30 min.

The sulfonylurea/metformin group exhibited the highest basal levels of active TGF-β (31.50 ± 3.58 ng/ml). The glargine/metformin group had active TGF-β levels (24.98 ± 1.90 ng/ml) that were comparable to those of the healthy participants (22.12 ± 2.34 ng/ml). The lowest basal levels of active TGF-β were detected in the DPP-4i/metformin group (12.28 ± 0.84 ng/ml). Following the intake of a standardized meal, active TGF-β levels decreased (approx. 30%) in healthy subjects as well as in the sulfonylurea/metformin group and in the glargine/metformin group. After 5 h, the active TGF-β levels were normalized to basal levels. Active TGF-β levels in the DPP-4i/metformin group did not change significantly after the test meal. Overall plasma levels of insulin and proinsulin were comparable between healthy participants, and T2DM patients in the glargin/metformin group and in the DPP4i/metformin group. However, no correlation between active TGF-β levels, glucose, insulin or pro-insulin levels was detected.

Conclusions

T2DM patients often exhibit elevated levels of pro-fibrotic active TGF-β. Our results suggest that glargine/metformin and DPP4i/metformin treatment may more effectively reduce active TGF-β serum levels than the sulfonylurea/metformin treatment.

【 授权许可】

   
2013 Pscherer et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
• [2]Standards of medical care in diabetes--2013 Diabetes Care 2013, 36(1):S11-66.
• [3]Lim AK, Tesch GH: Inflammation in diabetic nephropathy. Mediators Inflamm 2012, 2012:146154.
• [4]Koppel H, Riedl E, Braunagel M, Sauerhoefer S, Ehnert S, Godoy P, Sternik P, Dooley S, Yard BA: L-carnosine inhibits high-glucose-mediated matrix accumulation in human mesangial cells by interfering with TGF-beta production and signalling. Nephrol Dial Transplant 2011, 26:3852-3858.
• [5]Pscherer S, Larbig M, von Stritsky B, Pfutzner A, Forst T: In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment. J Diabetes Sci Technol 2012, 6:634-640.
• [6]Freude T, Braun KF, Haug A, Pscherer S, Stockle U, Nussler AK, Ehnert S: Hyperinsulinemia reduces osteoblast activity in vitro via upregulation of TGF-beta. J Mol Med (Berl) 2012, 90:1257-1266.
• [7]Tesseur I, Zou K, Berber E, Zhang H, Wyss-Coray T: Highly sensitive and specific bioassay for measuring bioactive TGF-beta. BMC Cell Biol 2006, 7:15. BioMed Central Full Text
• [8]Lawrence DA: Transforming growth factor-beta: a general review. Eur Cytokine Netw 1996, 7:363-374.
• [9]Massague J: TGF-beta signal transduction. Annu Rev Biochem 1998, 67:753-791.
• [10]Gressner AM, Weiskirchen R, Breitkopf K, Dooley S: Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002, 7:d793-807.
• [11]Robbins DC, Jaspan J, Vasquez B, Van Cauter E: Biphasic patterns of peripheral insulin and glucose levels after lunch in normal subjects. Diabetes Care 1987, 10:293-299.
• [12]Cortes P, Riser BL, Asano K, Rodriguez-Barbero A, Narins RG, Yee J: Effects of oral antihyperglycemic agents on extracellular matrix synthesis by mesangial cells. Kidney Int 1998, 54:1985-1998.
• [13]Giannico G, Cortes P, Baccora MH, Hassett C, Taube DW, Yee J: Glibenclamide prevents increased extracellular matrix formation induced by high glucose concentration in mesangial cells. Am J Physiol Renal Physiol 2007, 292:F57-65.
• [14]Zhu L, Cortes P, Hassett C, Taube DW, Yee J: Glibenclamide induces collagen IV catabolism in high glucose-stimulated mesangial cells. Exp Diabetes Res 2012, 2012:183535.
• [15]Lenski M, Kazakov A, Marx N, Bohm M, Laufs U: Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol 2011, 51:906-918.
• [16]Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS: Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012, 340:248-255.
• [17]Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A: The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med 1995, 1:74-79.